<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is associated with human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, especially those affecting the B cell compartment such as Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The virally encoded homolog of the mammalian pro-survival protein Bcl-2, BHRF1 contributes to <z:mp ids='MP_0001799'>viral</z:mp> infectivity and <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In addition to the pro-apoptotic <z:chebi fb="0" ids="30153">BH3</z:chebi>-only protein <z:chebi fb="3" ids="33173">Bim</z:chebi>, its key target in lymphoid cells, BHRF1 also binds a selective sub-set of pro-apoptotic proteins (Bid, Puma, Bak) expressed by host cells </plain></SENT>
<SENT sid="3" pm="."><plain>A consequence of BHRF1 expression is marked resistance to a range of cytotoxic agents and in particular, we show that its expression renders a mouse model of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> untreatable </plain></SENT>
<SENT sid="4" pm="."><plain>As current small organic <z:chebi fb="68" ids="48706">antagonists</z:chebi> of Bcl-2 do not target BHRF1, the structures of it in complex with <z:chebi fb="3" ids="33173">Bim</z:chebi> or Bak shown here will be useful to guide efforts to target BHRF1 in EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, which are usually associated with poor clinical outcomes </plain></SENT>
</text></document>